Medical Developments International (ASX:MVP), the maker of the Penthrox (methoxyflurane) ‘green whistle’, has announced the appointment of Brent MacGregor as its new CEO.
Mr MacGregor recently served with CSL's Seqirus as senior vice president for commercial operations.
He previously held a number of senior executive roles at Novartis, including CEO of the Novartis influenza vaccine business, president of Novartis Vaccines and head of North America.
“I have taken some time to do my due diligence and am very excited about the opportunities for MVP to capitalise on its global registration footprint," said Mr MacGregor.
"In Europe, the taking back of the business from Mundipharma is a big start in doing this. The breadth of MVP in Respiratory, Advanced manufacturing as well as its iconic Penthrox ‘green whistle’ see it very well positioned for growth well into the future. My family are also looking forward to coming back again to live in Australia.”
The chairman of Medical Developments International, Mr David Williams, said, “Brent’s role in the growth and globilisation of Seqirus, and his international experience are exactly the skillset we need to drive the next phase of MVP’s growth.
"It is a bonus that he has lived and worked in Australia before, and worked for an Australian company. We are very comfortable with his drive, his passion and the cultural fit.”
Acting CEO and director, Max Johnston, said, “I am delighted that Brent has agreed to join MVP and bring his global experience in healthcare at this exciting time in the company’s history. I look forward to working alongside him for the next few months whilst Brent relocates permanently. I am also looking forward to transferring to him all I have learned about the company working in it for the past 4 months. The strength of the business and the opportunities for growth are better than I had appreciated as a Director.”